Company Overview and News
KUALA LUMPUR: JF Apex Research expects Fitters Diversified Bhd , Datasonic Group Bhd , Cypark Resources Bhd , Benalec Holdings Bhd and CCK Consolidated Holdings Bhd to be among the stocks to watch on Thursday.
KUALA LUMPUR: Cypark Resources Bhd ’s wholly-owned unit Cypark RE Store Sdn Bhd will collaborate with 21st Century Clean Energy GmbH and Co KG, the authorised Tesvolt agent for Malaysia, to jointly expand their renewable energy business in the country.
KUALA LUMPUR: Cypark Resources Bhd will allocate up to RM200mil for capital expenditure (capex) for financial year ending Oct 31 (FY18) on projects related to the concession businesses that it had secured recently.
KUALA LUMPUR: GFM Services Bhd Spring Gallery Bhd, Dagang Nexchange Bhd (DNeX), Cypark Resources Bhd and Tenaga Nasional Bhd (TNB) are among the stocks to watch on Monday, according to JF Apex Research.
MarketWatch: The Dow Jones Industrial Average reached a record high on Monday, with banks and retailers surging and technology companies falling as investors realigned their portfolios in hopes of benefiting from expected corporate tax cuts.. The DJIA rose 0.24% to end at 24,290.05 points, the S&P 500 lost 0.11% to 2,639.44 and the Nasdaq dropped 72.22 points to end at 6,775.37. - Reuters
KUALA LUMPUR, Dec 4 — Cypark Resources Bhd announced that its wholly-owned subsidiary, Cypark Renewable Energy Sdn Bhd (CRE), had received a Letter of Acceptance of Offer from the Energy Commission (EC) for the development of large scale solar photovoltaic plant (PV) at Terip Dam, Negri Sembilan.
Growth prospects: UOB Kay Hian Research reckons Cypark has growth prospects now that it has transitioned from short-term contracts that are susceptible to economic cycles to concession-related activities.
KUALA LUMPUR: PublicInvest Research has downgraded Cypark Resources Bhd to “neutral” due to its limited upside.
KUALA LUMPUR (March 29): Shares of renewable energy firm Cypark Resources Bhd rose 2.22% in early trade this morning after it won three contracts worth RM28.48 million from the Department of National Solid Waste Management.
MarketWatch: US stocks ended sharply higher on Tuesday, with financial and energy shares surging as data showed US consumer confidence soaring to a more than 16-year high. The DJIA rose 150.52 points, or 0.73%, to 20,701.5, the S&P 500 gained 16.98 points, or 0.73%, to 2,358.57 and the Nasdaq added 34.77 points, or 0.6%, to 5,875.14. - Reuters Energy Oil prices rose as much as 2% on Tuesday after a severe disruption to Libyan oil supplies and as officials suggested Opec and other producing countries could extend an output-cuts deal to the end of the year.
KUALA LUMPUR (March 29): The FBM KLCI is expected to extend its gains today in tandem with the overnight gains at most global markets.
KUALA LUMPUR (March 28): Based on corporate announcements and news flow today, stocks in focus on Wednesday (March 29) may include: Perak Transit Bhd, Muar Ban Lee Group Bhd, United Malacca Bhd, Cypark Resources Bhd, Astro Malaysia Holdings Bhd, Kelington Group Bhd, UEM Edgenta Bhd, Econpile Holdings Bhd, Handal Resources Bhd and Anzo Holdings Bhd.
KUALA LUMPUR (March 9): The FBM KLCI remained in the negative zone at mid-morning today, weighed by index-linked banking as well as oil and gas-linked stocks.
KUALA LUMPUR (Jan 25): The FBM KLCI is expected to trend higher today and test the 1,690 level, riding on its current momentum and in line with the overnight gains at most global markets.
2018-05-25 - Asif
Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...
2018-05-25 - Asif
Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...